Clinical Hematology Research Development Program (K12) at Johns Hopkins

描述（由申请人提供）： 该提案旨在约翰霍普金斯医疗机构（JHMI）建立良性血液学临床血液学职业发展计划。良性血液学的下一代临床研究人员将需要包括具有技能，态度，早期研究培训和经验的个人，以利用良性血液学的快速发展。在开发该计划时，我们将使用已建立的研究基础设施，包括独立的儿科和内科血液学部门，致力于良性血液疾病的护理和研究，以及我们在约翰霍普金斯大学医学院和约翰霍普金斯大学彭博公共卫生学院的临床研究生培训计划（GTPCI）。我们的具体目标是：a）识别，培训和发展创造性和成功的临床研究者，有能力与，参与和领导参与临床研究的多学科团队，解决复杂的问题，并成为儿科，青少年和成人良性血液学的国家领导者; B）为学员提供必要的技能，知识，态度和经验，在良性血液学临床研究中取得成功。该培训将包括接触国家和国际领导人以及成功临床研究所需的多学科课程，包括良性血液学，临床试验设计，流行病学，统计学，研究伦理和人类受试者保护; c）提供丰富的指导环境。我们将整合JHMI的多个研究资源和研究人员，为学员提供最佳的研究经验和培训。我们将把我们的努力集中在六个领域，我们觉得有我们的机构内的特别优势：骨髓衰竭和干细胞生物学，镰状细胞病（SCD），骨髓增生性疾病，输血医学，结果研究和遗传学。我们将与几位知名的研究者和导师合作，为学员开发良性血液学结构化课程和强大的指导研究经验。仔细和广泛的指导将是这些努力的基石，接触到尖端的研究经验。通过该计划，我们的最终目标是提供一个临床研究人员的干部，谁将成为创造性的，独立的调查，照顾病人，并承担良性临床血液学的领导作用。

DESCRIPTION (provided by applicant): This proposal seeks to establish a Clinical Hematology Career Development Program in benign hematology at the Johns Hopkins Medical Institutions (JHMI). The next generation of clinical researchers in benign hematology will need to include individuals with the skills, attitudes, early research training and experience to capitalize on rapidly developing progress in benign hematology. In developing this program, we will use established research infrastructure, including free-standing Divisions of Hematology in Pediatrics and Internal Medicine that are dedicated to the care and study of benign hematologic disorders, as well as our Graduate Training Program in Clinical Investigation (GTPCI) at the Johns Hopkins University School of Medicine and Johns Hopkins University Bloomberg School of Public Health. Our specific aims are: a) To identify, train and develop creative and successful clinical investigators, with the capability to interact with, participate in, and lead multidisciplinary teams involved in clinical research, address complex problems and become national leaders in pediatric, adolescent and adult benign hematology; b) To provide trainees with the requisite skills, knowledge, attitude and experience for successful careers in clinical research in benign hematology. This training will include exposure to national and international leaders and curriculum in the multiple disciplines necessary for successful clinical research, including benign hematology, clinical trials design, epidemiology, statistics, research ethics and human subjects protection; c) To provide a rich mentoring environment. We will integrate multiple research resources and investigators available at the JHMI to provide optimal exposure of trainees to research experiences and training. We will focus our efforts in six areas where we feel there is particular strength within our institution: bone marrow failure and stem cell biology, sickle cell disease (SCD), myeloproliferative disorders, transfusion medicine, outcomes research and genetics. We will work with several established investigators and mentors to develop a structured curriculum in benign hematology and strong mentored research experiences for trainees. Careful and extensive mentoring will be the cornerstone of these efforts, with exposure to cutting edge research experiences. Through this program, we ultimately aim to provide a cadre of clinical researchers, who will become creative, independent investigators, care for patients and assume leadership roles in benign clinical hematology.